title: A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma.
abstract: Lenalidomide, an immunomodulatory drug that the US Food and Drug Administration (FDA) approved for the treatment of multiple myeloma, 5q- myelodysplasia and mantle-cell lymphoma (MCL), has encouraging efficacy in other B-cell malignancies. Its unique mechanism of action is in part due to altering the tumor microenvironment and potentiating the activity of T and natural-killer (NK) cells. Impressive clinical activity and excellent tolerability allows broad applicability. Lenalidomide has been used in a wide range of B-cell malignancies for years, but in 2013, the FDA marked its approval as a single agent only in relapsed/refractory mantle-cell lymphoma. Perhaps most impressive is the efficacy of lenalidomide when combined with monoclonal antibodies. Impressive efficacy and toxicity profiles with the combination of lenalidomide and rituximab in B-cell lymphomas in both the upfront and relapsed/refractory setting may allow a shift in our current treatment paradigm in both indolent and aggressive non-Hodgkin lymphoma (NHL). This review will summarize the current data in the relapsed/refractory and front-line setting of NHL with single-agent lenalidomide as well as its use in combination with other agents.
authors: Division of Hematology and Oncology, Department of Internal Medicine, NC, USA Department of Veterans' Affairs, Northern Carolina Healthcare System, NC, USA.
authors: Mili
authors: M
authors: Arora
authors: Division of Hematology and Oncology, Department of Internal Medicine, NC, USA.
authors: Sonia
authors: S
authors: Gowda
authors: Division of Hematology and Oncology, Department of Internal Medicine, Department of Veterans' Affairs, Northern Carolina Healthcare System, UC Davis Medical Center4501 X StreetSacramento, CA 95817, USA.
authors: Joseph
authors: J
authors: Tuscano
keywords: lenalidomide; non-Hodgkin lymphoma; rituximab